The challenge of new drug discovery for tuberculosis
Top Cited Papers
- 26 January 2011
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature
- Vol. 469 (7331), 483-490
- https://doi.org/10.1038/nature09657
Abstract
Tuberculosis (TB) is more prevalent in the world today than at any other time in human history. Mycobacterium tuberculosis, the pathogen responsible for TB, uses diverse strategies to survive in a variety of host lesions and to evade immune surveillance. A key question is how robust are our approaches to discovering new TB drugs, and what measures could be taken to reduce the long and protracted clinical development of new drugs. The emergence of multi-drug-resistant strains of M. tuberculosis makes the discovery of new molecular scaffolds a priority, and the current situation even necessitates the re-engineering and repositioning of some old drug families to achieve effective control. Whatever the strategy used, success will depend largely on our proper understanding of the complex interactions between the pathogen and its human host. In this review, we discuss innovations in TB drug discovery and evolving strategies to bring newer agents more quickly to patients.Keywords
This publication has 67 references indexed in Scilit:
- Letting SleepingdosLie: Does Dormancy Play a Role in Tuberculosis?Annual Review of Microbiology, 2010
- A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacyNature Communications, 2010
- An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosisNature, 2010
- Respiratory ATP synthesis: the new generation of mycobacterial drug targets?FEMS Microbiology Letters, 2010
- Biomarkers for tuberculosis disease activity, cure, and relapseThe Lancet Infectious Diseases, 2010
- Analysis of the Calculated Physicochemical Properties of Respiratory Drugs: Can We Design for Inhaled Drugs Yet?Journal of Chemical Information and Modeling, 2009
- PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO ReleaseScience, 2008
- Community-Based Therapy for Multidrug-Resistant Tuberculosis in Lima, PeruThe New England Journal of Medicine, 2003
- Therapeutic Implications of Drug Interactions in the Treatment of Human Immunodeficiency Virus‐Related TuberculosisClinical Infectious Diseases, 1999
- Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequenceNature, 1998